Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Artelo Biosciences ( (ARTL) ) is now available.
On May 11, 2026, Artelo Biosciences, Inc. notified R.F. Lafferty & Co., Inc. that it is terminating their at-the-market offering agreement, originally entered into on July 18, 2025, with the termination to become effective on May 18, 2026. Under this agreement, Artelo had the ability to sell up to $6.5 million of its common stock, but as of May 11, 2026, it had sold only 50,858 shares for gross proceeds of about $451,527, indicating that the company is stepping away from this specific capital-raising channel after using only a small portion of the available capacity.
The decision to end the R.F. Lafferty at-the-market facility suggests a shift in Artelo’s financing strategy or capital needs, which may affect how it accesses equity markets going forward. Stakeholders may interpret the limited use of the program and its termination as a sign that the company is exploring alternative funding sources, adjusting its dilution profile, or responding to market conditions that made further at-the-market sales less attractive.
The most recent analyst rating on (ARTL) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.
Spark’s Take on ARTL Stock
According to Spark, TipRanks’ AI Analyst, ARTL is a Neutral.
The score is primarily pressured by weak financial performance (no revenue, widening losses, and persistent cash burn with reliance on external financing). Technicals reinforce downside risk with the stock trading below all major moving averages, despite oversold signals. Valuation is difficult to anchor due to negative earnings, and recent corporate actions (bridge financing and reverse split with going-concern emphasis) add incremental risk.
To see Spark’s full report on ARTL stock, click here.
More about Artelo Biosciences
Artelo Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics, with its equity capital needs historically supported in part through at-the-market stock offering programs. The company accesses public markets by issuing common stock, allowing it to raise funds periodically to support its operations and pipeline development.
Average Trading Volume: 3,407,001
Technical Sentiment Signal: Sell
Current Market Cap: $2.2M
For a thorough assessment of ARTL stock, go to TipRanks’ Stock Analysis page.